-
1.
公开(公告)号:US07923556B2
公开(公告)日:2011-04-12
申请号:US12570010
申请日:2009-09-30
申请人: Stephen T. Wrobleski , Shuqun Lin , Katerina Leftheris , Liqi He , Steven P. Seitz , Tai-An Lin , Wayne Vaccaro
发明人: Stephen T. Wrobleski , Shuqun Lin , Katerina Leftheris , Liqi He , Steven P. Seitz , Tai-An Lin , Wayne Vaccaro
IPC分类号: C07D403/04 , C07D403/14 , A61K31/506 , A61P19/02 , A61K31/53 , C07D401/04 , C07D401/14
CPC分类号: C07D417/14 , C07D401/04 , C07D413/04 , C07D417/04
摘要: Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is —CR1; R1 is hydrogen or —CN; and N, G, Z, R2, R3, R4, R5, and R6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.
摘要翻译: 具有式(I)的化合物及其药学上可接受的盐及其溶剂合物可用作激酶抑制剂,其中:X1,X2和X3中的两个为N,X1,X2和X3中的其余一个为-CR1 ; R1是氢或-CN; 并且在说明书中描述了N,G,Z,R2,R3,R4,R5和R6。 还公开了含有式(I)化合物的药物组合物,以及治疗与p38激酶活性相关的病症和/或与LIM激酶活性相关的病症的方法。
-
2.
公开(公告)号:US20100029649A1
公开(公告)日:2010-02-04
申请号:US12570010
申请日:2009-09-30
申请人: Stephen T. Wrobleski , Shuqun Lin , Katerina Leftheris , Liqi He , Steven P. Seitz , Tai-An Lin , Wayne Vaccaro
发明人: Stephen T. Wrobleski , Shuqun Lin , Katerina Leftheris , Liqi He , Steven P. Seitz , Tai-An Lin , Wayne Vaccaro
IPC分类号: A61K31/5377 , C07D417/04 , A61K31/506 , A61P29/00 , A61P35/00 , C07D417/14 , A61K31/497 , A61K31/496 , C07D413/14
CPC分类号: C07D417/14 , C07D401/04 , C07D413/04 , C07D417/04
摘要: Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is —CR1; R1 is hydrogen or —CN; and N, G, Z, R2, R3, R4, R5, and R6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.
摘要翻译: 具有式(I)的化合物及其药学上可接受的盐及其溶剂合物可用作激酶抑制剂,其中:X1,X2和X3中的两个为N,X1,X2和X3中的其余一个为-CR1 ; R1是氢或-CN; 并且在说明书中描述了N,G,Z,R2,R3,R4,R5和R6。 还公开了含有式(I)化合物的药物组合物,以及治疗与p38激酶活性相关的病症和/或与LIM激酶活性相关的病症的方法。
-
3.
公开(公告)号:US20060178388A1
公开(公告)日:2006-08-10
申请号:US11344881
申请日:2006-02-01
申请人: Stephen Wrobleski , Shuqun Lin , Katerina Leftheris , Liqi He , Steven Seitz , Tai-An Lin , Wayne Vaccaro
发明人: Stephen Wrobleski , Shuqun Lin , Katerina Leftheris , Liqi He , Steven Seitz , Tai-An Lin , Wayne Vaccaro
IPC分类号: A61K31/506 , C07D239/32 , C07D403/02
CPC分类号: C07D417/14 , C07D401/04 , C07D413/04 , C07D417/04
摘要: Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is —CR1; R1 is hydrogen or —CN; and N, G, Z, R2, R3, R4, R5, and R6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.
摘要翻译: 具有式(I)的化合物及其药学上可接受的盐及其溶剂化物可用作激酶抑制剂,其中:X 1,X 2和X 2中的两个, SUB> 3
是N,X 1,X 2和X 3中的剩余的一个是-CR 1 SUB>; R 1是氢或-CN; 和N,G,Z,R 2,R 3,R 4,R 5和R 5, SUB> 6 SUB>在说明书中描述。 还公开了含有式(I)化合物的药物组合物,以及治疗与p38激酶活性相关的病症和/或与LIM激酶活性相关的病症的方法。 -
公开(公告)号:US20130023514A1
公开(公告)日:2013-01-24
申请号:US13638210
申请日:2011-03-30
申请人: Jay A. Markwalder , Brian E. Fink , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Steven P. Seitz
发明人: Jay A. Markwalder , Brian E. Fink , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Steven P. Seitz
IPC分类号: A61K31/53 , A61K31/5377 , A61K31/55 , A61P9/00 , A61P35/02 , A61P17/06 , A61P29/00 , A61P19/02 , C07D487/04 , A61P35/00
CPC分类号: C07D487/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D407/04 , C07D407/14 , C07D409/04 , C07D409/14 , C07D417/04 , C07D417/14
摘要: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
摘要翻译: 本发明提供式(I)化合物及其药学上可接受的盐。 式(I)吡咯并三嗪抑制蛋白激酶活性,从而使其成为抗癌剂。
-
公开(公告)号:US08791257B2
公开(公告)日:2014-07-29
申请号:US13638210
申请日:2011-03-30
申请人: Jay A. Markwalder , Brian E. Fink , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Steven P. Seitz
发明人: Jay A. Markwalder , Brian E. Fink , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Steven P. Seitz
IPC分类号: C07D487/04 , A61K31/53 , A61P19/02 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D407/04 , C07D407/14 , C07D409/04 , C07D409/14 , C07D417/04 , C07D417/14
CPC分类号: C07D487/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D407/04 , C07D407/14 , C07D409/04 , C07D409/14 , C07D417/04 , C07D417/14
摘要: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
摘要翻译: 本发明提供式(I)化合物及其药学上可接受的盐。 式(I)吡咯并三嗪抑制蛋白激酶活性,从而使其成为抗癌剂。
-
公开(公告)号:US20060252756A1
公开(公告)日:2006-11-09
申请号:US11477680
申请日:2006-06-29
申请人: Liqi He , Paul Gilligan , Robert Chorvat , Argyrios Arvanitis
发明人: Liqi He , Paul Gilligan , Robert Chorvat , Argyrios Arvanitis
IPC分类号: A61K31/53
CPC分类号: A61K31/53 , C07D487/04
摘要: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
-
公开(公告)号:US08252795B2
公开(公告)日:2012-08-28
申请号:US12575589
申请日:2009-10-08
申请人: Brian E. Fink , Libing Chen , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Andrew James Nation , Yufen Zhao , Litai H. Zhang
发明人: Brian E. Fink , Libing Chen , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Andrew James Nation , Yufen Zhao , Litai H. Zhang
IPC分类号: A01N43/58 , A61K31/50 , C07D487/00
CPC分类号: C07D487/04 , C07D498/04
摘要: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.
摘要翻译: 本发明提供式(I)化合物及其药学上可接受的盐。 式(I)咪唑并哒嗪抑制蛋白激酶活性,从而使其成为抗癌剂。
-
公开(公告)号:US07094782B1
公开(公告)日:2006-08-22
申请号:US10703235
申请日:2003-11-07
IPC分类号: A61K31/53 , C07D487/04 , C07D251/72
CPC分类号: A61K31/53 , C07D487/04
摘要: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
-
公开(公告)号:US20120283241A1
公开(公告)日:2012-11-08
申请号:US13552795
申请日:2012-07-19
申请人: Brian E. Fink , Libing Chen , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Andrew James Nation , Yufen Zhao , Litai H. Zhang
发明人: Brian E. Fink , Libing Chen , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Andrew James Nation , Yufen Zhao , Litai H. Zhang
IPC分类号: A61K31/5025 , A61P35/00 , A61P17/06 , A61K31/538 , A61P35/02 , A61K31/5377 , C07D498/04 , C07D487/04 , A61P29/00
CPC分类号: C07D487/04 , C07D498/04
摘要: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.
摘要翻译: 本发明提供式(I)化合物及其药学上可接受的盐。 式(I)咪唑并哒嗪抑制蛋白激酶活性,从而使其成为抗癌剂。
-
公开(公告)号:US20100113458A1
公开(公告)日:2010-05-06
申请号:US12575589
申请日:2009-10-08
申请人: Brian E. Fink , Libing Chen , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Andrew James Nation , Yufen Zhao , Litai H. Zhang
发明人: Brian E. Fink , Libing Chen , Ashvinikumar V. Gavai , Liqi He , Soong-Hoon Kim , Andrew James Nation , Yufen Zhao , Litai H. Zhang
IPC分类号: A61K31/5025 , C07D487/00
CPC分类号: C07D487/04 , C07D498/04
摘要: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.
摘要翻译: 本发明提供式(I)化合物及其药学上可接受的盐。 式(I)咪唑并哒嗪抑制蛋白激酶活性,从而使其成为抗癌剂。
-
-
-
-
-
-
-
-
-